Speakers

Expand/Collapse

Jim Brown
Chief Executive Officer
DURECT

Day Two

Thursday, July 15, 2021

1:00 pm | DUR-928, DNMTs and Alcohol-Associated Hepatitis

A. Ganesan
Professor
University of East Anglia

Day Two

Thursday, July 15, 2021

10:00 am | Targeting Two Erasers: Dual Inhibition of HDACs and LSD1

Gerd Hummel
Director of Drug Development
Oryzon Genomics

Michael-Christopher Keogh
Chief Scientific Officer
Epicypher

Day One

Wednesday, July 14, 2021

11:40 am | Next generation genomic mapping with CUTANA CUT&RUN

Ibrahim Jivanjee
Director of Product Management and Marketing
Arima Genomics, Inc

Day One

Wednesday, July 14, 2021

12:50 pm | Leverage the spatial properties of the genome to discover translational markers towards novel diagnostics, therapies and treatments.

Neil Michaud
Senior Director of Translational Medicine
Epizyme, Inc.

Day One

Wednesday, July 14, 2021

2:30 pm | Molecular Correlates of Response to TAZVERIK®: the Value of Translational Studies

Eric Campeau
Senior Director of Translational Medicine
Zenith Epigenetics

Day Two

Thursday, July 15, 2021

3:30 pm | Clinical Development of The BET Bromodomain Inhibitor ZEN- 3694 In Solid Tumors: Lessons Learned

Maria Hatziapostolou
Senior Lecturer
Nottingham Trent University

Day One

Wednesday, July 14, 2021

11:50 am | "Breaking” a lncRNA-Protein Complex as a Novel Approach to Target Cancer Metabolism

Iain Russell
Director of Marketing
Dovetail Genomics

Day One

Wednesday, July 14, 2021

11:00 am | From Mechanism of Action to Biomarker Discovery – how chromatin landscape informs the drug discovery process.

Ellen Filvaroff
Executive Director in Translational Development
Bristol-Myers Squibb

Day Two

Thursday, July 15, 2021

11:00 am | CC-90011, a Potent, Oral, & Reversible LSD1 Inhibitor

Elisabetta Chiarparin
Director - Medicinal Chemistry
AstraZeneca

Day Two

Thursday, July 15, 2021

2:00 pm | Discovery of Small Molecule Modulators of Epi Targets

Zariana Nikolova
Executive Director
Bristol Myers Squibb

Day Two

Thursday, July 15, 2021

11:00 am | CC-90011, a Potent, Oral, & Reversible LSD1 Inhibitor

Sylvie Guichard
Senior Director - Translational Science & Biology
Forma Therapeutics

Day One

Wednesday, July 14, 2021

1:30 pm | A Novel CBP/p300 Inhibitor for the Treatment of AR-driven Cancers

Drew Thompson
Vice President - Molecular Innovation & Pharmaceutical Development
Fulcrum Therapeutics

Day Two

Thursday, July 15, 2021

2:30 pm | Next Generation Drug Discovery at Fulcrum Therapeutics: FTX-6058, A Novel EED Inhibitor To Increase Fetal Hemoglobin Expression For the Treatment of Select Hemoglobinopathies

Chih-Ming Ho
Chief Technology Officer
KYAN Therapeutics

Day Two

Thursday, July 15, 2021

9:30 am | Global Optimization of Combinatorial Drug Enable by AI-PRS Platform

Johnathan R. Whetstine, PhD
Professor, Jack Schultz Basic Science Endowed Chair Director, Cancer Epigenetics Institute Program Co-leader Cancer Signaling and Epigenetics
Fox Chase Cancer Center

Day Two

Thursday, July 15, 2021

9:00 am | Epigenetics: A Gatekeeper for DNA Replication & ecDNA Amplification

Kai He
Assistant Professor of Medicine
Ohio State University Comprehensive Cancer

Day Two

Thursday, July 15, 2021

12:00 pm | Transitioning from Haematological to Solid Tumors

James Winkler
Vice President - Biology & Translational Medicine
OnKure Inc.

Day One

Wednesday, July 14, 2021

1:00 pm | OKI-179, an Oral Class 1-selective Depsipeptide HDAC Inhibitor: Phase 1 Results & Phase 2 Plans

Xuedong Liu
Professor, Department of Biochemistry, University of Colorado-Boulder and Co-Founder and SAB
OnKure Inc.

Day One

Wednesday, July 14, 2021

9:30 am | Panel Discussion - HDAC3, BET, RNA, So Many Targets – Exploring New Potential in Well Known Targets to Create New Value & Diversify Pipelines

Tamara Maes
Founder, Shareholder, VP of Board of Directors, & President of Scientific Advisory Board
Oryzon Genomics

Robert Soliva
Head of Drug Discovery
Oryzon Genomics

Day One

Wednesday, July 14, 2021

9:30 am | Panel Discussion - HDAC3, BET, RNA, So Many Targets – Exploring New Potential in Well Known Targets to Create New Value & Diversify Pipelines

Thomas Paul
Senior Director, Epigenetics Research
Pfizer

Day One

Wednesday, July 14, 2021

3:00 pm | Discovery of a First-in-Class KAT6A/KAT6B Inhibitor CTX-648 (PF-9363) with Potent Anti-Tumor Activity in ER+ Breast Cancer with KAT6A Dysregulation

9:30 am | Panel Discussion - HDAC3, BET, RNA, So Many Targets – Exploring New Potential in Well Known Targets to Create New Value & Diversify Pipelines

Aundrietta Duncan
Director, Non-Clinical Development
Salarius Pharmaceuticals

Day One

Wednesday, July 14, 2021

3:30 pm | Targeting FET-Rearranged Sarcomas Through Inhibition of LSD1

Alon Goren
Assistant Professor
University of California San Diego

Day Two

Thursday, July 15, 2021

4:00 pm | Designing Biomarkers That Enable Accurate Translation of Combination Therapies

Jiuzhou Song
Professor
University of Maryland

Day One

Wednesday, July 14, 2021

4:00 pm | Noncoding RNA & Epigenetics in Animal Health

Antonello Mai
Professor
University of Rome La Sapienza

Day Two

Thursday, July 15, 2021

11:30 pm | Epi-drugs in Parasites

Nikhil Ghate
Postdoctoral Research Associate
University of Southern California

Day One

Wednesday, July 14, 2021

10:00 am | Targeting Histone H2AThr120 Phosphorylation in Colon Cancer

Laura Banaszynski
Principal Investigator
University of Texas Southwestern Medical Center

Day Two

Thursday, July 15, 2021

1:30 pm | Phosphorylation of Histone H3.3 at Serine 31 Promotes p300 Activity

Ari Melnick
Professor
Weill Cornell - Cornell University

Day One

Wednesday, July 14, 2021

11:10 am | Precision Epigenetic Therapy for Blood Cancers